Search

Displaying results 2781 - 2790 of 8575 in total
  1. Drug

    Nirogacestat

    go.drugbank.com/drugs/DB12005
    ApprovedInvestigational

    Nirogacestat is a small-molecule gamma-secretase inhibitor that was investigated as a potential treatment for desmoid tumors. … It was previously granted breakthrough therapy, fast track, and orphan drug designations for the treatment of desmoid tumors, and the final approval was based on positive results obtained in the Phase

  2. Drug

    Trapidil

    go.drugbank.com/drugs/DB09283
    Experimental

    Trapidil, a platelet-derived growth factor antagonist, was originally developed as a vasodilator and anti-platelet agent and has been used to treat patients with ischemic coronary heart, liver, and kidney

  3. Drug

    Ragweed pollen extract

    go.drugbank.com/drugs/DB05368
    ApprovedWithdrawn

    Ragweed pollen extract has been developed by Curalogic. The company has initiated a phase III trial with its product for oral immunotherapy of ragweed allergy. … While traditional disease-modifying immunotherapeutics are administered by subcutaneous injection, Curalogic has developed a more convenient orally administered drug.

  4. Drug

    NOV-002

    go.drugbank.com/drugs/DB05393
    Investigational

    NOV-002 is approved and marketed in the Russian Fereration by Pharma BAM under the trade name Glutoxim. … NOV-002, the lead compound acts as a chemoprotectant and an immunomodulator, in combination with chemotherapy.

  5. Drug

    T487

    go.drugbank.com/drugs/DB05474
    Experimental

    The formulation is administered orally and has anti-inflammatory effects in conditions such as rheumatoid arthritis, inflammatory bowel disease and psoriasis.

  6. Drug

    Tiludronic acid

    go.drugbank.com/drugs/DB01133
    ApprovedVet approvedWithdrawn

    [A1923] Tiludronic acid was first described in the literature in 1988 as a potential treatment for Paget's disease of bone.[A202235] Tiludronic acid was granted FDA approval on 7 March 1997.[L4763]

  7. Drug

    Cenobamate

    go.drugbank.com/drugs/DB06119
    ApprovedInvestigational

    [L10653] Cenobamate was granted FDA approval on 21 November 2019.[L10653] … [A188442,L10653] The exact mechanism of action has not been described in the literature, though it positively modulates GABA<sub>A</sub> and inhibits voltage gated sodium channels.

  8. Drug

    Naldemedine

    go.drugbank.com/drugs/DB11691
    ApprovedInvestigational

    Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opioid-induced Constipation. … It is a modified form of [DB00704] to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier.

  9. Drug

    Tegoprazan

    go.drugbank.com/drugs/DB16690
    Investigational

    [A234220] It has also been observed to be efficacious independent of food intake.[A234220] … Tegoprazan (also known as CJ-12420) is a novel therapeutic developed by CJ Healthcare Corp for treating acid-related gastrointestinal diseases.

  10. Drug

    Ambroxol

    go.drugbank.com/drugs/DB06742
    ApprovedInvestigational

    Surfactants acts as an anti-glue factor by reducing the adhesion of mucus to the bronchial wall, in improving its transport and in providing protection against infection and irritating agents.